Reply - 15/08/11
Doi : 10.1016/j.jaci.2008.01.073
Ann C. Wu, MD a 
, A. David Paltiel, PhD b, Karen M. Kuntz, ScD c, Scott T. Weiss, MD, MS d, Anne L. Fuhlbrigge, MD d
, A. David Paltiel, PhD b, Karen M. Kuntz, ScD c, Scott T. Weiss, MD, MS d, Anne L. Fuhlbrigge, MD d a Department of Ambulatory Care and Prevention, Harvard Medical School, and Children’s Hospital, Boston, Mass
b Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, Conn
c Department of Health Policy and Management, Harvard School of Public Health, Boston, Mass
d Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass
Le texte complet de cet article est disponible en PDF.
| Supported by the National Heart, Lung, and Blood Institute through grant R01 HL68201-01A1. |
|
| Disclosure of potential conflict of interest: A. D. Paltiel has received research support from the National Institutes of Health. S. T. Weiss has received research support from the National Institutes of Health and Genentech. A. L. Fuhlbrigge is on the speakers’ bureau for GlaxoSmithKline and Merck, designed and analyzed studies for Novartis, was a member of Sepracor’s Data Safety Monitoring Board, and has received research support from Boehringer Ingelheim, GlaxoSmithKline, and Merck. The rest of the authors have declared that they have no conflict of interest. |
© 2008
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 121 - N° 6
P. 1514-1515 - juin 2008 Retour au numéro
Article précédent
- Questioning the economic evaluation of omalizumab
- Dennis Revicki, Ruth Brown, Peter Dale
- Anti-CD20 (rituximab) treatment for atopic eczema
- Anna Šedivá, Jana Kayserová, Eva Vernerová, Andrea Poloučková, Štěpánka Čapková, Radek Špíšek, Jiřina Bartůňková
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?